Biomarkers in Autoimmune Diseases of the Central Nervous System

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Apr 24

PMID 37090723

Authors

Fenghe Zhang

Xue Gao

Jia Liu

Chao Zhang

Affiliations

Soon will be listed here.

Abstract

The autoimmune diseases of the central nervous system (CNS) represent individual heterogeneity with different disease entities. Although clinical and imaging features make it possible to characterize larger patient cohorts, they may not provide sufficient evidence to detect disease activity and response to disease modifying drugs. Biomarkers are becoming a powerful tool due to their objectivity and easy access. Biomarkers may indicate various aspects of biological processes in healthy and/or pathological states, or as a response to drug therapy. According to the clinical features described, biomarkers are usually classified into predictive, diagnostic, monitoring and safety biomarkers. Some nerve injury markers, humoral markers, cytokines and immune cells in serum or cerebrospinal fluid have potential roles in disease severity and prognosis in autoimmune diseases occurring in the CNS, which provides a promising approach for clinicians to early intervention and prevention of future disability. Therefore, this review mainly summarizes the potential biomarkers indicated in autoimmune disorders of the CNS.

Citing Articles

Advancing CNS Therapeutics: Enhancing Neurological Disorders with Nanoparticle-Based Gene and Enzyme Replacement Therapies.

Liu S, Li H, Xi S, Zhang Y, Sun T Int J Nanomedicine. 2025; 20:1443-1490.

PMID: 39925682 PMC: 11806685. DOI: 10.2147/IJN.S457393.

Distinct plasma metabolomic signatures differentiate autoimmune encephalitis from drug-resistant epilepsy.

Xiong W, Yeo T, May J, Demmers T, Ceronie B, Ramesh A Ann Clin Transl Neurol. 2024; 11(7):1897-1908.

PMID: 39012808 PMC: 11251473. DOI: 10.1002/acn3.52112.

The murine meninges acquire lymphoid tissue properties and harbour autoreactive B cells during chronic Trypanosoma brucei infection.

Quintana J, Sinton M, Chandrasegaran P, Dubey L, Ogunsola J, Al Samman M PLoS Biol. 2023; 21(11):e3002389.

PMID: 37983289 PMC: 10723712. DOI: 10.1371/journal.pbio.3002389.

Continued dysregulation of the B cell lineage promotes multiple sclerosis activity despite disease modifying therapies.

Londono A, Mora C F1000Res. 2023; 10:1305.

PMID: 37655229 PMC: 10467621. DOI: 10.12688/f1000research.74506.2.

References

Weber M, Derfuss T, Metz I, Bruck W . Defining distinct features of anti-MOG antibody associated central nervous system demyelination. Ther Adv Neurol Disord. 2018; 11:1756286418762083. PMC: 5881972. DOI: 10.1177/1756286418762083. View

Canto E, Barro C, Zhao C, Caillier S, Michalak Z, Bove R . Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. JAMA Neurol. 2019; 76(11):1359-1366. PMC: 6692664. DOI: 10.1001/jamaneurol.2019.2137. View

Ciano-Petersen N, Cabezudo-Garcia P, Muniz-Castrillo S, Honnorat J, Serrano-Castro P, Oliver-Martos B . Current Status of Biomarkers in Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Int J Mol Sci. 2021; 22(23). PMC: 8658717. DOI: 10.3390/ijms222313127. View

Liang C, Chu E, Kuoy E, Soun J . Autoimmune-mediated encephalitis and mimics: A neuroimaging review. J Neuroimaging. 2022; 33(1):19-34. DOI: 10.1111/jon.13060. View

Raveney B, Oki S, Hohjoh H, Nakamura M, Sato W, Murata M . Eomesodermin-expressing T-helper cells are essential for chronic neuroinflammation. Nat Commun. 2015; 6:8437. PMC: 4600741. DOI: 10.1038/ncomms9437. View

Li M, Chen H, Yin P, Song J, Jiang F, Tang Z . Identification and Clinical Validation of Key Extracellular Proteins as the Potential Biomarkers in Relapsing-Remitting Multiple Sclerosis. Front Immunol. 2021; 12:753929. PMC: 8688859. DOI: 10.3389/fimmu.2021.753929. View

Gil-Perotin S, Castillo-Villalba J, Cubas-Nunez L, Gasque R, Hervas D, Gomez-Mateu J . Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis. Front Neurol. 2019; 10:1008. PMC: 6768010. DOI: 10.3389/fneur.2019.01008. View

Rosenstein I, Rasch S, Axelsson M, Novakova L, Blennow K, Zetterberg H . Kappa free light chain index as a diagnostic biomarker in multiple sclerosis: A real-world investigation. J Neurochem. 2021; 159(3):618-628. DOI: 10.1111/jnc.15500. View

Khalil M, Enzinger C, Langkammer C, Ropele S, Mader A, Trentini A . CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. Mult Scler. 2012; 19(4):436-42. PMC: 3652709. DOI: 10.1177/1352458512458010. View

10.

Ashtari F, Madanian R, Shaygannejad V, Zarkesh S, Ghadimi K . Serum levels of IL-6 and IL-17 in multiple sclerosis, neuromyelitis optica patients and healthy subjects. Int J Physiol Pathophysiol Pharmacol. 2020; 11(6):267-273. PMC: 6971496. View

11.

Gillinder L, Warren N, Hartel G, Dionisio S, OGorman C . EEG findings in NMDA encephalitis - A systematic review. Seizure. 2019; 65:20-24. DOI: 10.1016/j.seizure.2018.12.015. View

12.

Wang J, Liu J, Li R, Wang C . Research and progress on biomarkers of neuromyelitis optica spectrum disorders. J Recept Signal Transduct Res. 2020; 41(5):417-424. DOI: 10.1080/10799893.2020.1830109. View

13.

Yang S, Zhang C, Zhang T, Feng B, Jia D, Han S . A real-world study of interleukin-6 receptor blockade in patients with neuromyelitis optica spectrum disorder. J Neurol. 2022; 270(1):348-356. DOI: 10.1007/s00415-022-11364-9. View

14.

Watanabe M, Nakamura Y, Michalak Z, Isobe N, Barro C, Leppert D . Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology. 2019; 93(13):e1299-e1311. DOI: 10.1212/WNL.0000000000008160. View

15.

Chatterjee M, Schild D, Teunissen C . Contactins in the central nervous system: role in health and disease. Neural Regen Res. 2018; 14(2):206-216. PMC: 6301169. DOI: 10.4103/1673-5374.244776. View

16.

Cubas-Nunez L, Gil-Perotin S, Castillo-Villalba J, Lopez V, Solis Tarazona L, Gasque-Rubio R . Potential Role of CHI3L1+ Astrocytes in Progression in MS. Neurol Neuroimmunol Neuroinflamm. 2021; 8(3). PMC: 7931642. DOI: 10.1212/NXI.0000000000000972. View

17.

Benkert P, Meier S, Schaedelin S, Manouchehrinia A, Yaldizli O, Maceski A . Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol. 2022; 21(3):246-257. DOI: 10.1016/S1474-4422(22)00009-6. View

18.

Aktas O, Smith M, Rees W, Bennett J, She D, Katz E . Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. Ann Neurol. 2021; 89(5):895-910. PMC: 8252046. DOI: 10.1002/ana.26067. View

19.

Stampanoni Bassi M, Iezzi E, Landi D, Monteleone F, Gilio L, Simonelli I . Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course. J Neurol. 2018; 265(11):2540-2547. DOI: 10.1007/s00415-018-8994-5. View

20.

Petrzalka M, Meluzinova E, Libertinova J, Mojzisova H, Hanzalova J, Rockova P . IL-2, IL-6 and chitinase 3-like 2 might predict early relapse activity in multiple sclerosis. PLoS One. 2022; 17(6):e0270607. PMC: 9236235. DOI: 10.1371/journal.pone.0270607. View